We are experiencing the exciting time of the genome era.For our work this means being able to contextualize the alterations of each genetic network in the natural environment of a specific tumor and identify the key driving modules on which specific tumor subgroups rely for growth,survival and progression.With this information in hand,we can target the critical alterations with specific drugs,often already available for other types of diseases.By focusing on one of the most lethal forms of human tumors,the glioblastoma multiforme(GBM),we have been able to make incredible progress along this line in the last two years.Our work in this area first discovered two transcription factors – Stat3 and C/EBP – that are responsible for activation and maintenance of the most aggressive gene expression signature of high-grade glioma,the mesenchymal signature.The therapeutic implication of this work has been our ability to efficient target the two transcription factors in preclinical mouse models with consequent collapse of the mesenchymal signature and extended survival.More recently,we have identified the first examples of highly oncogenic and recurrent gene fusions in GBM,target their dependency in a particular tumor subtype,and observe dramatic anti-tumor effects.Recurrent gene fusions in GBM result in the constitutive activation of receptor tyrosine kinase genes(FGFR,EGFR and NTRK1)that render tumors addicted to the driver events.Among them,the FGFR-TACC gene fusion is the addicting oncogenic event with the highest therapeutic value.First,are recurrent oncogenic events in several types of human cancer beside GBM(head & neck,lung,bladder,etc.).Second,FGFR-TACC fusions are potent oncogenes that transform normal cells by activation of non-canonical substrates and precipitation of aneuploidy.Finally,human tumors harboring FGFR-TACC fusions acquire marked sensitivity to FGFR inhibitory compounds.It is not surprising that this line of investigation has matured towards clinical trials.The integrated computational-experimental pipeline that we developed plus our ability to functionalize any genetic brain tumor module was recently applied to the entire landscape of CNVs,somatic mutations and gene fusions of human GBM.This information is quickly advancing our ability to translate each new genetic finding into the personalized context of the clinical setting.